Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Think Research Corporation THKKF


Primary Symbol: V.THNK

Think Research Corporation is a Canada-based company that offers digital health software solutions. It is a provider of cloud-based data, knowledge, and software solutions primarily delivered as software-as-a-service (SaaS) to healthcare delivery systems and the practitioners that they support. Its operations are organized into three lines of business: Software and Data Solutions, Clinical Research, and Clinical Services. Its SaaS solutions help patients find, navigate, and connect to health services across large governments and payer clients, while also ensuring safety for prescribed medications at pharmacies. Through its wholly owned subsidiary, BioPharma Services Inc., the Company provides research data and analysis derived from Phase I clinical trials, bioequivalence studies and bioanalytical services. Its clinics act as a test bed for its software and technology, transforming them with digital solutions that optimize clinical outcomes, streamline workflows, and optimize billing.


TSXV:THNK - Post by User

Post by dt_coreon Sep 19, 2022 2:52pm
179 Views
Post# 34971860

Analyst Estimate Changes vs. Initiation

Analyst Estimate Changes vs. InitiationI took a look at some of the initiation reports on THNK published by analysts to see what had changed from their 2023 estimates and also how it compares to the companies updated guidance run-rate exiting 2022. I'll spare the details by generally these are my observations:

1. The average out-of-the gate target pric on THNK was $6.00 or thereabouts. which roughly translated into an EV/S multiple of 4.0x 2023 numbers and an EV/EBITDA of 30x. Those are fairly lofty valuation metrics in today's markets so adjusting for something more reasonable in the current environment (e.g. 1.5x trough to 2.0x more normalized EV/S multiple. I also looked at EV/EBITDA multiples) would have produced a target price of $2.50 on the low end to $3.20 based on the original estimates for the company. In other words, the decline from $6.00 to $2.50/$3.20 is all due to valuation contraction in the markets.

2. Next I looked at how estimates changed based on updates from the company and guidance and a few things jump out. First EBITDA estimates for 2023 haven't really changed that much at around $8.1M for 2023. What has changed is the amount of revenue (higher now), number of shares (higher now), Cash on balance sheet (lower by about $10M) and level of indebtedness (higher now). So essentially more dilution for shareholders and lower forecasted margins albeit off of a higher revenu base. Net, net the new estimates at current market multiples suggest a $1.50 to $2.25 target price.

So based on the reasoning above the decline in THNK's target price from what investors thought at the time of the IPO can be roughly explained as 75% due to market forces and 25% due to declining expectations of corporate fundamentals. That tells me that when markets recover (eventually) we could see a lot of positive movement on the shareprice providing that management delivers on current expected fundamentals.
<< Previous
Bullboard Posts
Next >>